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We investigated the associations with HLA and microtubule-associated protein tau (MAPT)
H1 haplotype in anti-IgLON5 disease, a recently identified disorder characterized by gait
instability, brainstem dysfunction, and a prominent sleep disorder in association with IgLON5
antibodies and pathologic findings of a novel neuronal-specific tauopathy.
Methods
We compared the HLA alleles and MAPT H1/H1 genotype of 35 patients with anti-IgLON5
with healthy controls. The on-line server tool NetMHCIIpan 3.1 was used to predict the
IgLON5 peptide binding to HLA Class II molecules.
Results
The HLA-DRB1*10:01-DQB1*05:01 haplotype was overrepresented in patients with anti-
IgLON5 disease (OR = 54.5; 95% CI: 22.2–133.9, p < 0.0001). In addition, HLA-DQA was
genotyped in 27 patients, and 25 (92.6%) of them had DQ molecules composed by DQA1*01
and DQB1*05 chains compared with 148/542 (27.3%) controls (OR = 43.9; 95% CI:
10.4–185.5, p < 0.0001). Patients DRB1*10:01 positive developed more frequently sleep or
bulbar symptoms than those carrying other HLA alleles (70.0% vs 26.7%; p = 0.011). Prediction
algorithms identified 2 IgLON5 peptides (1 located in the signal sequence) that showed strong
binding to HLA-DRB1*10:01 and other HLA-DRB1, but not to HLA-DQA and HLA-DQB
molecules. The MAPT H1/H1 homozygous genotype was present in 20/24 (83.3%) anti-
IgLON5 Caucasian patients compared with 54/116 (46.5%) healthy controls (p = 0.0007).
Conclusions
The robust association of anti-IgLON5 disease with distinct HLA Class II molecules supports
a primary autoimmune origin. The significant association ofMAPTH1 haplotype also suggests
that an underlying neurodegenerative process could be involved in anti-IgLON5 disease.
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The anti-IgLON5 disease is a recently identified neurologic
disorder, characterized by progressive gait instability, brain-
stem dysfunction, and a characteristic sleep disorder. The
biological hallmark of this disease is the presence of antibodies
against IgLON5, a neural cell adhesion molecule of unknown
function.1 Neuropathologic studies demonstrated a novel
neuronal tauopathy with predominant involvement of the
hypothalamus and brainstem.2 Although these findings favor
a primary tauopathy, the presence of highly specific antibodies
against a neuronal surface protein and the tight association of
the disease with HLAs DRB1*10:01and DQB1*05:01 (pre-
viously shown in 15 patients) alternatively suggested an
immune-mediated pathogenesis.3
Familial forms of tauopathies are caused by mutations in the
microtubule-associated protein tau (MAPT) gene.4 In addi-
tion, the frequency of the MAPT H1/H1 homozygous ge-
notype has been described to be consistently increased in
sporadic tauopathies including progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD), but its fre-
quency in IgLON5 disease is unknown.5,6
It is also unknown whether the HLA alleles associated with
anti-IgLON5 disease can present IgLON5 peptides to
generate a specific autoimmune response.7 We report here
the identification of IgLON5 peptides with potential
binding to HLA Class II molecules using in silico techni-
ques. In addition, we performed DNA sequencing analyses
of the MAPT gene and determined the association with
the H1 haplotype and examined whether the most preva-
lent HLA allele (HLA-DRB1*10:01) in patients with anti-




The study includes 35 patients with IgLON5 antibodies
identified in the Neuroimmunology Laboratory of the In-
stitute of Biomedical Research August Pi i Sunyer (IDI-
BAPS), Hospital Clinic (Barcelona, Spain). Genomic DNA
of 28 patients was available for HLA andMAPT analysis. For
the remaining 7 patients, HLA-DR genotyping was per-
formed elsewhere and the information used for analysis of
HLA-DR frequencies and association with specific neuro-
logic symptoms. Methods of detection of IgLON5 anti-
bodies and collection of clinical information have been
previously reported.1,3 The frequency of HLA and MAPT
haplotypes in patients was compared with that of healthy
Caucasian Spanish controls (542 controls for the HLA study
and 116 for the MAPT genotyping).
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Hospital Clinic Ethics
Committee. All patients or proxies gave written informed
consent for the storage and use of serum, CSF, and clinical
information for research purposes.
HLA genotyping
HLA Class I and Class II genotyping was performed by
techniques based on DNA-PCR and polymorphism identifi-
cation by reverse hybridization with specific probes and fluo-
rescence labeling of hybridized fragments (polymerase chain
reaction [PCR]-sequence-specific oligonucleotide probes)
(Immucor GTI Diagnostics Inc., Waukesha) in combination
with genomic DNA sequencing by Sanger methodology
(PCR-sequenced-based typing) (SuBiTo, Inno-Train Diag-
nostik GmbH and the software HiType, Kronberg, Germany),
providing an unambiguous resolution of the 2 fields that define
the HLA molecule polymorphism according to the WHO
official current nomenclature (hla.alleles.org/nomenclature/
nomenc_updates.html).
MAPT genetic studies
Genotyping of genomic DNA was performed using the prede-
signed TaqMan assay for MAPT rs1800547 (A/G), which
defines theH1/H2 haplotypes and run on a StepOne Plus Real-
time PCR System (Applied Biosystems, Foster City, CA) as
previously described.8 Twenty-seven patients with DNA avail-
able and 116 healthy controls were genotyped. All but 3 patients
were of European Caucasian origin. In addition, in 7 patients
with anti-IgLON5, we performed a mutational screening of
MAPT exons 1, 9, 10, 11, 12, and 13, where pathogenic muta-
tions have been previously identified in several neurodegener-
ative diseases including frontotemporal dementia or PSP.4 We
performed a touchdown PCR amplification on a PTC-100 PCR
(MJ Research; Watertown, MA) using 20–50 ng of total ge-
nomicDNA and using primer pairs as previously described.9We
used the BigDye Terminator v3.1 Cycle Sequencing Kit
according to the manufacturer’s instructions (Applied Bio-
systems, Foster City, CA). Sequences were run on an ABI3100
automatic sequencer (Applied Biosystems, Foster City, CA) and
analyzed using the DNA baser v4.36.0 software (dnabaser.com).
HLA-IgLON5 peptide binding prediction
The human IgLON5 sequence was retrieved fromUNIPROT
database entry A6NGN9 (uniprot.org) encompassing the
signal peptide (amino acid positions 1–30) and the mature
protein (amino acid positions 31–336). The on-line server
tool NetMHCIIpan 3.1 was used for the prediction of
IgLON5 peptide binding to HLA Class II molecules (cbs.dtu.
dk/services/NetMHCIIpan/).10 The full protein sequence
was submitted as 15-residue overlapping fragments with 1 gap
Glossary
CBD = corticobasal degeneration; MAPT = microtubule-associated protein tau; PSP = progressive supranuclear palsy.
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residue at the N-terminal flanking position. Binding was
considered strong if the predicted IC50 (half maximal in-
hibitory concentration) value was <50 nM and ranked <1%
among 200.000 random peptides. Only strong binders were
taken for analysis.10–12 Because the 9-residue binding core is
contained in several 15-mer peptides, only the strongest
predicted binder of any series of 15-mer peptides with
a 9-residue or longer overlap was used for calculations.
Binding prediction was calculated with the 15 different HLA-
DRB1 alleles present in patients (*10:01, *01:01, *01:02, *03:
01, *04:01, *04:03, *07:01, *09:01, *11:01, *12:01, *13:01, *14:
01, *14:04, *15:01, and *16:01). Because of the strong linkage
disequilibrium between DRB1 and DQ alleles, the NetMH-
CIIpan 3.1 algorithmwas also applied to the DQ alleles. The 4
possible combinations for each individual were considered,
combining each DQA1 with DQB1 alleles present in 1 patient
in cis and/or trans, considering both chromosomes.
Molecular modeling of HLA Class II-IgLON5
peptide interactions
To confirm the HLA-IgLON5 peptide binding predictions
generated by the NetMHCIIpan 3.1 program, molecular
modeling of complexes including HLA-DRB1*10:01 and *01:
01 and the 2 IgLON5 peptides identified as strong binders
was performed using a simulation protocol (appendix e-1,
links.lww.com/NXI/A136).
Statistical analysis
OR with 95% CI was calculated to measure the association of
HLA alleles andMAPT haplotypes with anti-IgLON5 disease.
ForMAPT haplotypes, we performed a genotypic association
analysis using unconditional logistic regression models, as
implemented in SNPstat software, to compare the frequencies
of MAPT H1/H1—which is the risk genotype described in
other tauopaties (CBD or PSP)—with the other 2 genotypes
H1/H2 and H2/H2 in patients with anti-IgLON5 and con-
trols (dominant model). The χ2 test and Fisher exact prob-
ability test were used to determine the significance of
differences in the distribution of the clinical features between
patients who were HLA-DRB1*10:01 positive or carried other
DRB1* alleles. The nonparametric Mann-Whitney U test was
used to compare medians. p Values < 0.05 were considered
significant. The statistical analyses were performed using
commercially available software (SPSS, Version 22.0).
Data availability
Data from patients reported within the article are available
and will be shared anonymously by request from any qualified
investigator.
Results
HLA subtypes in anti-IgLON5 disease
General information and the HLA and MAPT genotyping of
the 35 patients with anti-IgLON5 disease are summarized in
table 1. The median age at disease onset was 63 years (range:
42–81 years), and 51% were female. Thirty-two patients were
of European Caucasian origin. The countries of origin were
Spain (12 patients), Austria (8), Germany (7), Brazil (2),
France (1), Belgium (1), Italy (1), Australia (1), India (1),
and Philippines (1). Twenty of the 35 patients (57.1%) car-
ried the HLA-DRB1*10:01-DQB1*05:01 haplotype com-
pared with 2.4% of healthy controls (OR = 54.5; 95% CI:
22.2–133.9, p < 0.0001). Another 7 patients (20%) carried the
DRB1*01:01 allele (2 were homozygous, and 1 heterozygous
with DRB1*10:01) representing a similar frequency seen in
controls (14.1%) (p = 0.34). The DRB1*03:01 allele was
present in 8 patients (22.9%) (2 were also DRB1*10:01
positive) representing a similar frequency observed in con-
trols (20.6%) (p = 0.75). The remaining 3 patients had other
HLA-DRB1 (table 1). HLA-DQA was genotyped in 27
patients, and 25 (92.6%) of them had DQ molecules com-
posed by DQA1*01 and DQB1*05 chains compared
with 148/542 (27.3%) controls (OR = 43.9; 95% CI:
10.4–185.5, p < 0.0001). Although the high frequency of these
alleles could be partially explained by its genetic linkage with
the HLA-DRB1*10:01 allele (allelefrequencies.net), the
DQA1*01/DQB1*05 molecule was present in 11/13 (84.6%)
patients without DRB1*10:01.
HLA Class I alleles were studied in 27 patients with anti-
IgLON5 (table 1). Five patients (18.5%) were HLA-B*37:
01 compared with 17 controls (3.1%) (OR = 7.0; 95% CI:
2.4–20.8; p = 0.0004). The allele HLA-A*01:01 was also
overrepresented in patients with anti-IgLON5 compared
with controls (47.4% vs 20.5%; OR = 2.7; 95% CI: 1.2–5.9;
p = 0.01). These associations were expected considering
the strong linkage disequilibrium of these 2 alleles
with DRB1*10:01 that conform a common haplotype in
Caucasians.13
Association of the HLA-DRB1*10:01 allele with
neurologic symptoms
Next, we investigated whether the presence of the most
prevalent HLA-DRB1*10:01 allele associated with distinct
clinical features (table 2). At disease onset, 14 DRB1*10:01-
positive patients (70%) presented with sleep or bulbar clinical
phenotypes. Conversely, these 2 phenotypes tended to be less
frequent (26.7%) in patients with other HLA alleles, who
often presented with a PSP-like phenotype or cognitive im-
pairment. Accordingly, a trend to a higher frequency of par-
asomnia, sleep breathing alterations, and bulbar dysfunction
was observed in DRB1*10:01 carriers. Dysautonomia tended
also to be more frequent in DRB1*10:01 carriers, whereas
cognitive impairment occurred more frequently in non-
DRB1*10:01 carriers. Improvement with immunotherapy
occurred in 5 (26.3%) of 19 patients. DRB1*10:01-negative
patients showed a trend to a better response to immuno-
therapy (3 of 5 cases improved). IgG subclass predominance
was IgG4 in all DRB1*10:01-negative patients compared with
70% in DRB1*10:01-positive cases (p = 0.027).
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Table 1 Clinical characteristics, HLA genotyping, and tau haplotype
N Age, sex Syndromea HLA-A HLA- HLA-B HLA-B HLA-C HLA-C HLA-DRB HLA-DRB HLA-DQA HLA-DQA HLA-DQB HLA-DQB Tau haplotype
11,3 59, M Sleep 11:01 66:01 27:05 35:01 01:02 04:01 10:01 11:01 01:05 05:05 05:01 03:01 H1/H1
21,3 54, M Sleep 01:01 29:02 27:05 37:01 01:02 06:02 10:01 14:01 01:05 —b 05:01 05:03 H1/H1
31,3 54, M Sleep 32:01 68:01 27:05 37:01 02:02 06:02 10:01 13:01 01:03 01:05 05:01 06:01 H1/H1
41,3 76, M Bulbar 01:01 24:02 08:01 15:01 03:03 15:01 10:01 11:01 01:02 05:01 05:01 03:01 H1/H1
53 42, M Bulbar 01:01 02:01 37:01 44:02 05:01 06:02 10:01 04:01 01:01 03:02 05:01 03:01 H1/H1
6 53, F Sleep 01:01 02:11 15:07 40:06 07:01 12:02 10:01 03:01 01:01 05:01 05:01 02:01 H1/H1
73 65, F Cognitive 02:01 66:03 07:02 44:03 02:02 04:01 10:01 13:01 01:01 01:03 05:01 06:03 H1/H1
83 53, F Sleep 23:01 24:02 13:02 50:01 06:02 —b 10:01 07:01 01:01 02:01 05:01 02:02 H1/H1
93 49, M Sleep 01:01 02:01 07:02 44:02 05:01 07:01 10:01 01:01 01:01 —b 05:01 —b H1/H1
10 65, M Sleep 01:01 03:01 07:02 37:01 07:01 07:02 10:01 15:01 01:01 01:02 05:01 06:02 H1/H2
113 64, M Bulbar ND ND ND ND ND ND 10:01 UNK ND ND 05:01 UNK ND
123 62, F Bulbar ND ND ND ND ND ND 10:01 03:01 ND ND 05:01 02:01 ND
13 64, M PSP-like ND ND ND ND ND ND 10:01 UNK ND ND 05:01 UNK ND
143 61, F Cognitive ND ND ND ND ND ND 10:01 07:01 ND ND 05:01 02:02 ND
153 63, F Sleep ND ND ND ND ND ND 10:01 13:01 ND ND 05:01 06:03 ND
16 68, M Bulbar ND ND ND ND ND ND 10:01 UNK ND ND 05:01 UNK ND
17 57, M PSP-like 02:01 11:01 37:01 44:02 06:02 07:04 10:01 12:01 01:01 05:05 05:01 03:01 H1/H1
18 70, M Bulbar 02:01 30:02 07:05 18:01 05:01 15:05 10:01 13:01 01:03 01:04 05:01 06:03 H1/H2
1927 75, F Cognitive 03:01 33:01 14:02 55:01 03:03 08:02 10:01 04:01 01:04 03:01 05:01 03:02 H1/H1
20 62, F Ataxia 01:01 03:01 18:01 41:01 07:01 17:01 10:01 09:01 01:04 03:02 05:01 03:03 H1/H1
21 80, F Cognitive 02:01 25:01 15:01 44:02 03:03 05:01 01:01 14:01 01:01 —b 05:01 05:03 H2/H2
22 60, M Stiff-person 01:01 02:01 35:01 51:01 04:01 14:02 01:01 —b 01:01 —b 05:01 —b ND
23 62, M Sleep 03:01 26:01 39:01 56:01 01:02 12:03 01:01 11:01 01:01 05:05 05:01 03:01 H1/H1
24 52, F Ataxic gait 01:01 02:01 37:01 57:01 06:02 —b 01:01 —b 01:01 —b 05:01 —b H1/H2


































Table 1 Clinical characteristics, HLA genotyping, and tau haplotype (continued)
N Age, sex Syndromea HLA-A HLA- HLA-B HLA-B HLA-C HLA-C HLA-DRB HLA-DRB HLA-DQA HLA-DQA HLA-DQB HLA-DQB Tau haplotype
26 62, M Cognitive 02:01 29:02 35:01 44:03 04:01 16:01 01:01 07:01 01:01 02:01 05:01 02:02 H1/H1
27 69, M PSP-like 01:01 29:01 07:02 08:01 07 15 03:01 14:01 01:04 05:01 05:03 02:01 H1/H1
283 65, M PSP-like 02:05 30:02 18:01 50:01 05:01 06:02 03:01 07:01 02:01 05:01 02:01 03:03 H1/H1
29 71, M Bulbar 01:01 25:01 08:01 18:01 07:01 12:03 03:01 04:01 03:01 05:01 02:01 03:02 H1/H1
30 67, F PSP-like 01:01 24:02 08:01 14:02 07:01 08:02 03:01 01:02 01:01 05:01 05:01 02:01 H1/H1
31 66, F Bulbar 02:01 11:01 14:02 18:01 07:01 08:02 03:01 14:01 01:04 05:01 05:03 02:01 H1/H1
321,3 69, F Sleep 01 32 08 15 03 07 03:01 16:01 ND ND 05:02 02:01 H1/H1
33 81, F PSP-like 24:02 —b 35:02 35:03 04:01 12:03 04:03 14:01 01:01 03:02 05:03 03:01 H1/H1
34 67, F Cognitive 11:01 —b 35:01 51:01 04:01 —b 04:03 14:01 01:01 03:02 05:03 03:01 H1/H1
353 69, F Cognitive 11:01 34:01 38:02 39:01 07:02 12:02 09:01 14:04 01:01 03:02 05:03 03:03 H2/H2
Abbreviations: F = female; M = male; ND = not done; PSP = progressive supranuclear palsy; UNK = unknown.
Seventeen patients have been previously reported (references 1, 3, and 27).
a Syndromes were defined as described.3 Patient 22 presented with a different syndrome characterized by fasciculations, cramps, and stiffness in the lower limbs reminiscent of stiff-person syndrome (sleep, bulbar, gait, and
cognitive symptoms were absent).































HLA-IgLON5 peptide binding prediction
The binding ability of IgLON5 peptide sequences to 15
HLA-DRB1 alleles using the NetMHCIIpan 3.1 server
showed that only 3 DRB1 molecules, the DRB1*01:01,
DRB1*10:01, and DRB1*09:01, were strong binders for the
same 2 IgLON5-derived peptides (table 3). The epitope
with the strongest predicted affinity was LRLLAAAAL,
belonging to the signal peptide of IgLON5. The second
epitope, IVHVPARIV, is located in the Ig-like 2 domain of
the protein. Seven different HLA-DRB1 molecules also had
a predicted binding capacity for one of these peptides,
mainly IVHVPARIV. Another peptide (WTSDPRVRL)
showed binding capacity for only HLA-DRB1*03:01 pres-
ent in 8 patients (table 3). No IgLON5 peptide sequences
were defined as strong binders considering all possible, cis
or trans, combinations of the DQA and DQB molecules.
Similarly, no IgLON5 peptide sequences were binders to
HLA Class I–associated alleles A*01:01 and B*37:01 using
the NetMHC 3.4 server.14
Given that the signal peptide sequence may vary among
different family members and isoforms of a protein family,
we determined the prediction of binding to HLA Class II
molecules the signal peptide sequences of the other mem-
bers of the IgLON family, IgLON1, 2, 3, and 4. In contrast to
the IgLON5 peptide LRLLAAAAL, none of the other signal
peptide sequences showed strong predicted binding affinity.
Only sequences from isoforms 1, 2, 5, 7, and 9 of IgLON2
(Uniprot accession NP-057606.1, NP_001041674.1, NP_
001338930.1, NP_001338932.1, and NP_001338934.1,




(n = 15) p Value
Age at onset (y) 62 (42–76) 67 (52–81) 0.069a
Male sex 12 (60) 5 (33.3) 0.12b
Age at diagnosis (y) 64.5 (46–77) 71 (61–83) 0.023a
Chronic presentationd 17 (85) 9 (60) 0.13c
Sleep or bulbar profile vs others 14 (70) 4 (26.7) 0.011b
Parasomnia 14 (70) 4 (26.7) 0.011b
Sleep breathing disorder 19 (95) 8 (53.3) 0.011c
Bulbar dysfunction 17 (85.5) 8 (53.3) 0.062c
Gait difficulties 12 (60) 9 (60) 1.0b
Cognitive impairment 9 (45) 12 (80) 0.036b
Oculomotor abnormalities 10 (50) 8 (53.3) 0.84b
Dysautonomia 12 (60) 4 (26.7) 0.05b
Chorea 3 (15) 2 (13.3) 1.0c
CSF pleocytosis (>5 cells)e 5/17 (29.4) 1/12 (8.3) 0.35c
Elevated proteins (>45 mg/dL)e 10/17 (58.8) 5/12 (41.7) 0.36b
Anti-IgLON5 negative in CSFf 1/18 (5.6) 2/14 (15.4) 0.57c
IgG4-predominant IgG subclass 14 (70) 15 (100) 0.027c
Tau H1/H1 haplotype 12/14 (85.7) 9/12 (75) 0.63c
Response to immunotherapyg 2/14 (14.3) 3/5 (60) 0.084c
Disease duration (mo)h 44.5 (9–180) 96 (8–228) 0.24a
Death 6 (30) 3 (20) 0.7c
Data are presented as median and (range) or in number and (%).
a Mann-Whitney U test.
b χ2 test.
c Fisher exact test was used.
d Time from symptom onset to initial medical consultation >4 mo.
e CSF analysis was performed in 29 of 35 patients.
f IgLON5 antibodies were tested in CSF in 32 patients; in 3 (9.4%) of them, the antibodies were only detectable in serum.
g Immunotherapy was performed in 18 of 35 patients. Clinically significant improvement occurred in 5 (26.3%).
h Time from symptom onset until the last visit or death.
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respectively) resulted in weak predicted binding affinities to
HLA-DRB1 alleles. The second epitope, IVHVPARIV, was
not present in any of the other members of the IgLON
family.
Because tau protein deposits have been described in the
brain of patients with anti-IgLON5 antibodies who un-
derwent autopsy, a prediction study was also made on the
binding ability of tau protein sequences (Uniprot P10636)
to the indicated HLA-DRB1 and DQA-DQB alleles. No
sequences with high affinity for HLA molecules were
identified.
Molecular modeling of HLA Class II-IgLON5
peptide interactions
We next modeled the interaction of the strong binder
IgLON5 peptide LRLLAAAAL with DRB1*01:01 and
DRB1*10:01. The computed structure-based scores for the
binding of this peptide to DRB1*01:01 andDRB1*10:01 were
−97 and −91 kJ/mol, respectively. Although based on fun-
damentally different principles, this finding agrees with the
NetMHCIIpan 3.1 binding affinity predictions, thus sug-
gesting a slightly higher affinity of LRLLAAAAL for
DRB1*01:01 than for DRB1*10:01. Taking the structure into
account, the clearest differences between the pockets in the
peptide-binding grooves of DRB1*01:01 andDRB1*10:01 are
probably found in pocket P9, where there is absence of a well-
defined pocket in DRB1*10:01, whereas a shallow pocket is
visible in DRB1*01:01 (figure).
The computed scores for the binding of the other strong
binder peptide IVHVPARIV to DRB1*01:01 and DRB1*10:
01 were −75 and −57 kJ/mol, respectively. In this case, the
difference of 18 kJ/mol is significantly larger than that pre-
dicted by NetMHCIIpan 3.1. Nevertheless, using any of these
2 methods, a higher affinity for DRB1*01:01 is predicted.
Comparing the values obtained for the 2 peptides, we also
found that both methods predicted a higher affinity of
LRLLAAAAL than IVHVPARIV for either of the 2 HLA
molecules. Considering the binding scores of IVHVPARIV
relative to LRLLAAAAL, and given that the other anchoring
residues are significantly conserved, we conclude that Arg (R)
in pocket P7 is likely the main responsible for the lower
binding affinity of IVHVPARIV relative to LRLLAAAAL for
the 2 HLA molecules.
Genetic analysis of the MAPT gene in anti-
IgLON5 disease
The MAPT H1/H1 homozygous genotype was signifi-
cantly overrepresented with respect to H1/H2 and H2/H2
in 27 anti–IgLON5-positive patients (81.5% were H1/H1)
compared with 116 healthy controls (46.5% H1/H1), OR
5.05 (95% CI: 1.79–14.25), p = 0.0007. Similar results
were found when the sample was limited to the 24 anti–
IgLON5-positive patients of European Caucasian origin
(83% H1/H1) (p = 0.0007). Finally, we did not find
mutations in the commonly mutatedMAPT exons 1, 9, 10,
11, 12, and 13 in a subset of 7 patients with anti-IgLON5
disease.








DRB1*10:01 GARLRLLAAAALAGL LRLLAAAAL 11.04 0.04
QVYLIVHVPARIVNI IVHVPARIV 30.04 0.80
DRB1*01*01 GARLRLLAAAALAGL LRLLAAAAL 2.71 0.01
QVYLIVHVPARIVNI IVHVPARIV 4.29 0.25
DRB1*09:01 GARLRLLAAAALAGL LRLLAAAAL 28.19 0.30
QVYLIVHVPARIVNI IVHVPARIV 35.39 0.50
DRB1*03:01 GNDRWTSDPRVRLLI WTSDPRVRL 40.89 0.50
DRB1*04:01 GARLRLLAAAALAGL LRLLAAAAL 47.65 0.90
DRB1*07:01 QVYLIVHVPARIVNI IVHVPARIV 12.11 0.17
DRB1*12:01 QVYLIVHVPARIVNI IVHVPARIV 2.74 0.25
DRB1*13:01 QVYLIVHVPARIVNI IVHVPARIV 12.43 0.01
DRB1*14:01 QVYLIVHVPARIVNI IVHVPARIV 24.24 0.12
DRB1*14:04 QVYLIVHVPARIVNI IVHVPARIV 20.03 0.30
DRB1*15:01 QVYLIVHVPARIVNI IVHVPARIV 20.45 0.17
Binding of epitopes of IgLON5was predicted usingNertMHCIIpan 3.1 server in accordancewith the instruction of the server. Binding affinity below 50 nMand
a rank <1% among 200.000 random peptides was associated with strong binders. In bold, the 3 DRB1 molecules that bind to both IgLON5 peptides.
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Discussion
Anti-IgLON5 disease was the first among multiple CNS
disorders associated with antibodies against synaptic
receptors or neuronal surface proteins in which an associ-
ation with HLA Class II alleles was identified.1 Here, we
confirm the association with HLA-DRB1*10:01-DQB1*05:
01 alleles in a larger series of patients and provide several
novel findings that help to understand the interplay be-
tween the autoimmune and neurodegenerative processes of
the disease. First, the HLA-DRB1*10:01 was strongly as-
sociated with anti-IgLON5 disease and was found more
prevalent in patients who presented with parasomnias,
sleep breathing disorder, or bulbar symptoms. Second, 2
IgLON5 peptides showed high affinity for the HLA-DRB1
molecules identified in patients with the disease as pre-
dicted by an algorithm using artificial neural networks.
These findings were confirmed by molecular modeling
using the 2 IgLON5 peptides and DRB1*01:01 and
DRB1*10:01, the 2 alleles that showed the strongest affinity
for these peptides. Last, the MAPT H1/H1 genotype was
overrepresented in patients with anti-IgLON5 disease.
The robust association between anti-IgLON5 disease and
distinct HLA alleles supports a primary autoimmune event
as cause of the disease. One of the hypotheses to explain the
link between antibody-mediated diseases and specific HLA-
DR or DQ alleles is that these molecules present peptides of
the antibody-targeted antigen to autoimmune-prone CD4+
T cells, which in turn induce B-cell proliferation and dif-
ferentiation into antibody-secreting cells.15 In anti-IgLON5
disease, there is an overrepresentation of DRB1*10:01; this
is an infrequent allele that in all population studies repre-
sents less than 5% of individuals (allelefrequencies.net). The
DRB1*10:01 allele has been linked to an increased risk of
several rheumatological autoimmune diseases.16 Indeed, in
HLA-DRB1*10:01–positive patients with rheumatoid ar-
thritis and antibodies against citrullinated type II collagen,
CD4+ T cells are activated when a peptide from citrullinated
type II collagen protein is presented to T cells by DRB1*10:
01 but not by other DRB1 molecules showing the fine
specificity of the peptide-binding motifs of the HLA
molecules.17
The present study shows that the DRB1 alleles identified in
patients with anti-IgLON5 disease, DRB1*01:01 and
DRB1*10:01, are predicted to bind with high affinity 2
peptides of IgLON5. Molecular modeling of the interaction
of the 2 IgLON5 peptides (LRLLAAAAL and IVHV-
PARIV) with the strongest binding with DRB1*01:01 and
DRB1*10:01 confirmed the high affinity of this binding.
LRLLAAAAL corresponds to a sequence of the signal
peptide of IgLON5. Unlike other members of the IgLON
family, only the IgLON5 signal peptide region showed
a high binding affinity for DRB1 molecules. Signal peptides
contain numerous hydrophobic residues that help to anchor
the nascent polypeptide to the membrane.18 Once the
protein is anchored in the membrane, the signal sequence is
cleaved and degraded in the cytosol, and the resulting
peptides are known to be strong binders of the T-cell acti-
vating MHC Class I molecules. Indeed, signal peptides have
been proposed as adjuvants in vaccination strategies.19
Thus, although the epitope recognized by the helper T cell
(e.g., signal recognition peptide) must be linked to that
recognized by the B cell (surface peptide of the same anti-
gen, recognized by antibodies), the 2 cells do not need to
recognize identical epitopes, a phenomenon called linked
recognition.20 The in silico techniques to assess potential
binding of specific IgLON5 peptides to HLA molecules
used in the present study represent an exploratory com-
putational tool that will require its confirmation in future
immunologic experiments assessing the proliferative T-cell
response to the selected IgLON5 peptides.
Despite the DQA1*01/DQB1*05 haplotype was strongly
associated with anti-IgLON5 disease, no IgLON5 peptide
could be defined as a strong binder for these HLA alleles.
This association can only be partially explained by linkage
disequilibrium with the DRB1*10:01 allele, as 84.6% of
the patients non-DRB1*10:01 carriers were positive for
DQA1*01/DQB1*05. No IgLON5 peptide could be defined
either to be a binder to HLA Class I–associated alleles
Figure Modeling of the interaction between Class II mole-
cules and IgLON5 peptides
Detail of the pockets P7 and P9 in themodeled complexes between peptides
LRLLAAAAL (A) and IVHVPARIV (B) of IgLON5 and molecules HLA-DRB1*01:
01 andHLA-DRB1*10:01. Residues 7–9 (from right to left) of the peptides are
represented as sticks, with the carbons in golden yellow. Protein residues
forming the pockets are represented as sticks, with carbon atoms in teal
blue. Covering the protein atoms, their Connolly surface is represented to
facilitate the visualization of the pockets. Noncarbon atoms are colored as
follows: N-blue, H-light gray, O-red, and S-yellow. It can be observed that P9
(cavity at the left of each panel) is shallower in HLA-DRB1*10:01 than in HLA-
DRB1*01:01. As a result, the aliphatic residues at position 9 of both peptides
bindmore deeply in HLA-DRB1*01:01. Themodels also show that the Arg (R)
residue at position 7 in IVHVPARIV is too bulky for the small P7 and has to
orient its side chain toward previous pockets, particularly in HLA-DRB1*10:
01.
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(HLA-A*01:01, B*37:01). In this case, the association is
probably due to linkage disequilibrium of these Class I alleles
with the DRB1*10:01 allele. Peptide binding to HLA Class I
molecules implies antigenic presentation to CD8+ cytotoxic
T cells,21 but there are no data suggesting a role of CD8+
T cells in anti-IgLON5 disease.
Although this series is relatively small, we noted a trend to an
association between DRB1*10:01 and sleep and bulbar dys-
function as predominant symptoms at disease onset.1 Indeed,
although 78% (14/18) of patients with these clinical pre-
sentations hadDRB1*10:01, this haplotype was only observed
in 36% (5/14) of patients who initially presented with PSP-
like symptoms or cognitive deterioration. With the increasing
number of reports on patients with IgLON5 antibodies, it is
becoming evident that this disease is heterogeneous and that
the sleep disorder that was characterized in the initial series is
not always present.22 Clinical heterogeneity occurs in many
diseases, and the cause is probably multifactorial; however, the
genetic background plays an important role in some disorders.
For example, distinct HLA-DRB1 alleles appear to influence
the clinical phenotype of inclusion body myositis or the spinal
cord lesion load in MS.23,24
DRB1*10:01 is in strong linkage disequilibrium with
DQB1*05 alleles that associate with some IgG4-related dis-
eases such as MuSK antibody–mediated myasthenia.25
IgLON5 antibodies are predominantly of the IgG4 subclass,
but we found that in up to 30% of DRB1*10:01-positive
patients, the percentage of IgG1 was higher than that of IgG4.
Whether the IgG subclass predominance in anti-IgLON5
disease associates with different HLA haplotypes should also
be assessed in future studies.
An unexpected observation in anti-IgLON5 disease was that
the brain of the first 3 autopsied patients showed a novel tau-
opathy with neuronal accumulation of hyperphosphorylated
tau preferentially involving the hypothalamus and the teg-
mental nuclei of the brainstem.2 A subsequent case report
suggested that the tauopathy is not a constant finding and that
it could be a late event in the evolution of the disease.26 The
absence of neuronal tau deposits in early stages of the disease
perhaps could explain that some patients improve with im-
munotherapy and that brain biopsies showed inflammatory
infiltrates without tau pathology.27,28
Independently of whether autoimmunity or neurodegeneration
is the first pathogenic event, our current findings suggest that
patients with anti-IgLON5 disease may have a genetic associa-
tion with the MAPT H1/H1 genotype. Patients with this ge-
notype are susceptible to several neurodegenerative diseases,
particularly tauopathies (PSP and CBD) and synucleinopathies
such as Parkinson disease and multiple system atrophy.29 There
is robust evidence that inflammation plays a critical role in some
neurodegenerative diseases, and it has been postulated that it is
required for the progression of the degenerative process.30
Thus, it is conceivable that in anti-IgLON5 disease, the initial
event is an inflammatory autoimmune response that results in
a stress situation in patients susceptible to neurodegenerative
processes, eventually leading to the indicated tauopathy. How-
ever, our finding related to MAPT association must be taken
with caution due to the relative low number of patients and the
potential genetic heterogeneity among different populations.
Future validation studies of the MAPT H1/H1 genotype as-
sociation with anti-IgLON5 disease are warranted.
In summary, the tight association of anti-IgLON5 disease
with the DRB1*10:01-DQB1*05:01 haplotype and its high
affinity for IgLON5 peptides, particularly the peptide in the
signal sequence of IgLON5, strongly support that the disease
is autoimmune. Neuronal tau deposits might occur due to
a genetic predisposition of the patients, supported by the
association with the MAPT H1/H1 genotype. We have
previously shown that IgLON5 antibodies cause an irre-
versible antibody-mediated internalization of surface
IgLON5 in cultured hippocampal neurons.31 Therefore,
a task for the future is to determine how antibody disruption
of IgLON5 ultimately leads to neuronal accumulation of
hyperphosphorylated tau.
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